Valuation: Genome & Company

Market Cap 169B 115M 102M 94.36M 86.93M 163M 11.15B 166M 1.12B 439M 5.46B 433M 424M 19B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 151B 103M 91.02M 84.38M 77.73M 146M 9.97B 148M 1.01B 392M 4.89B 387M 379M 16.99B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
82.79%
Yield 2024 *
-
Yield 2025 -
Apr. 13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
Apr. 02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
Mar. 12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-07-16 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-01-24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-8.91%
1 week+2.90%
Current month-3.37%
1 month-16.27%
3 months-38.85%
6 months-62.59%
Current year-45.78%
1 week 3,320
Extreme 3320
4,225
1 month 3,320
Extreme 3320
4,545
Current year 3,320
Extreme 3320
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 53 2015-09-23
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap.
5/9/25 Free

Public Communications Manager

50,000 0.1608%
5/9/25 Don

Founder

90,000 0.2895%
5/9/25 Free 20,000 0.0643%
Change 5-day change 1-year change 3-year change Capi.($)
-8.91%+2.90%+27.30%-46.98% 116M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average -0.69%+1.46%+51.90%+90.22% 24.54B
Weighted average by Cap. +0.47%+0.92%+75.29%+136.55%

Financials

2024 2025
Net sales 27.74B 18.98M 16.73M 15.51M 14.29M 26.8M 1.83B 27.22M 185M 72.11M 898M 71.22M 69.69M 3.12B 24.59B 16.82M 14.83M 13.74M 12.66M 23.75M 1.62B 24.12M 164M 63.9M 796M 63.11M 61.76M 2.77B
Net income -20.11B -13.76M -12.13M -11.24M -10.36M -19.43M -1.33B -19.73M -134M -52.27M -651M -51.63M -50.52M -2.26B -6.43B -4.4M -3.88M -3.59M -3.31M -6.21M -425M -6.31M -42.82M -16.71M -208M -16.5M -16.15M -723M
Net Debt -48.91B -33.45M -29.49M -27.34M -25.19M -47.24M -3.23B -47.98M -326M -127M -1.58B -126M -123M -5.5B -17.86B -12.22M -10.77M -9.99M -9.2M -17.26M -1.18B -17.52M -119M -46.42M -578M -45.85M -44.87M -2.01B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
26-07-24 ₩3,730.00 -8.91% 266,975
26-07-23 ₩4,095.00 +6.36% 346,206
26-07-22 ₩3,850.00 +8.76% 267,352
26-07-21 ₩3,540.00 +1.72% 284,528
26-07-20 ₩3,480.00 -4.00% 162,711
  1. Stock Market
  2. Stocks
  3. A314130 Stock